Business
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
HOUSTON, March 26, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a status update of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation. Sustained inflammatory responses driven by dysfunctional immune regulation is a
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here","length":221,"tagName":"p","attribs":{}},{"type":"text","content":"Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function","length":153,"tagName":"p","attribs":{}},{"type":"text","content":"The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study","length":193,"tagName":"p","attribs":{}},{"type":"text","content":"Funded by the Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer, with Coya holding exclusive rights for clinical application","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, March 26, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today provides a status update of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation. Sustained inflammatory responses driven by dysfunctional immune regulation is a hallmark of serious autoimmune and neurodegenerative diseases.","length":600,"tagName":"p"},{"type":"text","content":"Fred Grossman, DO, Coya’s Chief Medical Officer commented: "Our Treg focused pipeline continues its advancement with the goal of manufacturing an allogeneic (off the shelf) specific modality that has the potential to be a first-in-class disease-modifying treatment for devastating neurodegenerative diseases of high unmet need. This approach complements and adds to our pipeline of therapies, including COYA-302, that aim to enhance Tregs and suppress neuroinflammation to slow progression in several neurodegenerative diseases."","length":539,"tagName":"p"},{"type":"text","content":"Arun Swaminathan, CEO of Coya, stated, "We believe Treg exosomes are complementary to and will provide accretive value t...